Portal Venous Gas After Trans-arterial Radioembolization in Hepatocellular Carcinoma: A Rare but Critical Imaging Finding

Transarterial radioembolization (TARE) is a relatively new treatment option available for unresectable hepatocellular carcinoma (HCC). TARE therapy involves the delivery of radiation directly to the tumor to cause tumor necrosis. Yttrium-90 (Y90) is commonly used as a source of radioembolization in TARE. TARE is very well tolerated and has a low rate of complications. Main complications of TARE for HCC include postembolization syndrome and radiation-induced injury to nearby organs such as the liver, gallbladder, and stomach, causing hepatitis, cholecystitis, or gastric ulceration. A side effect not previously described in TARE literature is portal venous gas after TARE therapy. We present the first ever reported case of portal and variceal venous gas in a 77-year-old male patient who had unresectable HCC and had previously failed chemotherapy. He underwent Y90 TARE for HCC. Following TARE, he presented with right upper quadrant abdominal pain, and imaging showed portal and variceal venous gas. He was treated with antibiotics, with resolution of symptoms and improvement in portal and variceal venous gas on repeat imaging.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2025-07-16
DOI
https://doi.org/10.7759/cureus.88107
Primary Topic
Liver Disease and Transplantation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Portal Venous Gas After Trans-arterial Radioembolization in Hepatocellular Carcinoma: A Rare but Critical Imaging Finding

Rajan Shah, Muhammad Aziz, Ahmed Ali Aziz, Ijlal Akbar Ali et al.
Cureus
Liver Disease and Transplantation
article

Portal Venous Gas After Trans-arterial Radioembolization in Hepatocellular Carcinoma: A Rare but Critical Imaging Finding

Rajan Shah, Muhammad Aziz, Ahmed Ali Aziz, Ijlal Akbar Ali, Nosheen Omar
article en

Abstract

Transarterial radioembolization (TARE) is a relatively new treatment option available for unresectable hepatocellular carcinoma (HCC). TARE therapy involves the delivery of radiation directly to the tumor to cause tumor necrosis. Yttrium-90 (Y90) is commonly used as a source of radioembolization in TARE. TARE is very well tolerated and has a low rate of complications. Main complications of TARE for HCC include postembolization syndrome and radiation-induced injury to nearby organs such as the liver, gallbladder, and stomach, causing hepatitis, cholecystitis, or gastric ulceration. A side effect not previously described in TARE literature is portal venous gas after TARE therapy. We present the first ever reported case of portal and variceal venous gas in a 77-year-old male patient who had unresectable HCC and had previously failed chemotherapy. He underwent Y90 TARE for HCC. Following TARE, he presented with right upper quadrant abdominal pain, and imaging showed portal and variceal venous gas. He was treated with antibiotics, with resolution of symptoms and improvement in portal and variceal venous gas on repeat imaging.

CureusVol. 17(7)
University of Kentucky (US), Regional Medical Center (US), Bay Medical Center (US), Capital Health (US)
Good health and well-being
Openalex Percentile: Top 75%
Liver Disease and Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.